EGFR and non-small cell lung carcinoma: A valuable example of this application is the ability of AI to discriminate targeted epidermal growth factor receptor (EGFR) mutations from the wild type in non-small-cell lung cancer (NSCLC) by using the PET/CT-based DL model, allowing for accurate patient selection and the delivery of appropriate therapy [26,28].